The FRAXA Drug Validation Initiative (FRAXA-DVI) provides speedy, cost-effective, objective preclinical testing of potential Fragile X treatments. FRAXA-DVI uses in-vitro systems, behavior batteries, and gene expression and peripheral biomarker platforms to validate investigational new drugs and repurposed available compounds in Fragile X syndrome (FXS). The post FRAXA Drug Validation Initiative (FRAXA-DVI) appeared first on FRAXA Research Foundation - Finding a Cure for Fragile X Syndrome.
